SCHEMBL29658170

SCHEMBL29658170

CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)O)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 11/20 0.71
KDM4E B2RXH2 1/20 0.67
TLR4 O00206 1/20 0.67
MEN1 O00255 1/20 0.67
ALDH1A1 P00352 1/20 0.67
LMNA P02545 1/20 0.67
TP53 P04637 1/20 0.67
TYMS P04818 1/20 0.67
GLA P06280 1/20 0.67
POLB P06746 1/20 0.67
HMGB1 P09429 1/20 0.67
MAPT P10636 1/20 0.67
FOLR2 P14207 1/20 0.67
FOLR1 P15328 1/20 0.67
HPGD P15428 1/20 0.67
ALOX15 P16050 1/20 0.67
ALOX12 P18054 1/20 0.67
GART P22102 1/20 0.67
APEX1 P27695 1/20 0.67
CASP1 P29466 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL221621 1.00 DHFR (0.71) DHFRKDM4ETLR4MEN1ALDH1A1
Hydrochloric Acid SCHEMBL1230259 0.99 DHFR (0.70) DHFRKDM4ETLR4MEN1ALDH1A1
Hydrochloric Acid SCHEMBL3171572 0.98 DHFR (0.69) DHFRKDM4ETLR4MEN1ALDH1A1
SCHEMBL30110296 0.92 DHFR (0.62) DHFRKDM4ETLR4MEN1ALDH1A1
SCHEMBL11913611 0.91 DHFR (0.71) DHFRKDM4ETLR4MEN1ALDH1A1
SCHEMBL13985918 0.91 DHFR (0.71) DHFRKDM4ETLR4MEN1ALDH1A1
SCHEMBL13529957 0.91 DHFR (0.60) DHFRKDM4ETLR4MEN1ALDH1A1
SCHEMBL10379252 0.90 DHFR (0.59) DHFRKDM4ETLR4MEN1ALDH1A1
SCHEMBL14753789 0.89 DHFR (0.66) DHFRKDM4ETLR4MEN1ALDH1A1
SCHEMBL22201137 0.88 HDAC4 (0.70) DHFRKDM4ETLR4MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115561355-B Method for detecting neutralizing antibody of carboxypeptidase G2 and detection system based on LC-MS/MS 重庆迪纳利医药科技有限责任公司 2024-04-30 CN claimed
CN-117607306-A Method and kit for simultaneously detecting methotrexate and various metabolites thereof 长沙都正生物科技股份有限公司 2024-02-27 CN claimed
CN-115561355-A Method for detecting neutralizing antibody of carboxypeptidase G2 and LC-MS/MS-based detection system 重庆迪纳利医药科技有限责任公司 2023-01-03 CN claimed
EP-3630994-B1 SENSORS, METHODS AND KITS FOR DETECTING NADPH BASED ON RESONANCE ENERGY TRANSFER. MAX PLANCK GESELLSCHAFT (DE) 2022-08-10 EP claimed
US-20260104979-A1 PLATFORM ASSISTED OS/WORKLOAD AGNOSTIC OPTIMAL MEMORY TIERING ACROSS NODES FOR DISTRIBUTED APPLICATIONS DELL PRODUCTS LP (US) 2026-04-16 US disclosed
US-20260000771-A1 PSMA-TARGETING LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME TARGIMMUNE THERAPEUTICS AG (CH) 2026-01-01 US disclosed
US-20260000700-A1 TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME TARGIMMUNE THERAPEUTICS AG (CH) 2026-01-01 US disclosed
WO-2025238236-A1 POLYPLEXES OF NUCLEIC ACIDS AND TARGETED CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL TARGIMMUNE THERAPEUTICS AG (CH) 2025-11-20 WO disclosed
EP-4615511-A1 TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME TargImmune Therapeutics AG (CH) 2025-09-17 EP disclosed
EP-4615510-A1 POLYPLEXES OF NUCLEIC ACIDS AND TARGETED CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL TargImmune Therapeutics AG (CH) 2025-09-17 EP disclosed
EP-4615509-A1 PSMA-TARGETING LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME TargImmune Therapeutics AG (CH) 2025-09-17 EP disclosed
US-20250255991-A1 SYNTHESIS AND COMPOSITION OF PHOTODYNAMIC THERAPEUTIC AGENTS FOR THE TARGETED TREATMENT OF CANCER ON TARGET LABORATORIES INC (US) 2025-08-14 US disclosed
CN-116209476-A Antifolate linker-drug and antibody-drug conjugates 拜奥迪斯私人有限公司 2023-06-02 CN disclosed
WO-2023079142-A2 TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME TARGIMMUNE THERAPEUTICS AG (CH) 2023-05-11 WO disclosed
CN-115561355-A Method for detecting neutralizing antibody of carboxypeptidase G2 and LC-MS/MS-based detection system 重庆迪纳利医药科技有限责任公司 2023-01-03 CN disclosed
CN-111748505-B Genetically engineered bacterium for expressing carboxypeptidase G2 and preparation method and application thereof 上海医药工业研究院 2022-12-30 CN disclosed
US-20220241429-A1 Antifolate-Carrying Nanoparticles and Their Use in Medicine MIDATECH LTD (GB) 2022-08-04 US disclosed
CN-114810343-A Misfire detection apparatus for internal combustion engine 丰田自动车株式会社 2022-07-29 CN disclosed
CN-114629388-A LC resonance suppression method based on virtual admittance remodeling 哈尔滨工业大学 2022-06-14 CN disclosed
US-20220160712-A1 METHODS OF TREATING RHEUMATOID ARTHRITIS AND FOR PREDICTING THE RESPONSE TO METHOTREXATE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2022-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250255991-A1 SYNTHESIS AND COMPOSITION OF PHOTODYNAMIC THERAPEUTIC AGENTS FOR THE TARGETED TREATMENT OF CANCER ERAL1, TK2, PYCR1 DHFR 148/4885KDM4E 4669/4885TLR4 639/4885
US-20260104979-A1 PLATFORM ASSISTED OS/WORKLOAD AGNOSTIC OPTIMAL MEMORY TIERING ACROSS NODES FOR DISTRIBUTED APPLICATIONS NPM1, DAPK1, APP DHFR 1370/4885KDM4E 4141/4885TLR4 2591/4885
US-20260000771-A1 PSMA-TARGETING LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME PSMA1, PSMA3, PSMA2 DHFR 371/4885KDM4E 3243/4885TLR4 2860/4885
US-20260000700-A1 TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME CTDSP1, POLM, MCTS1 DHFR 576/4885KDM4E 4503/4885TLR4 1793/4885
US-20220241429-A1 Antifolate-Carrying Nanoparticles and Their Use in Medicine FOLR1, FOLR2, SLC19A1 DHFR 4/4885KDM4E 4710/4885TLR4 2854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.